Inhibiting the AURKB enzyme significantly improves multiple measures of blood flow in rats with pulmonary arterial ...

Also in 2026, we expect to share updates from our Phase 2 trial of brensocatib in hidradenitis suppurativaa, from several of our gene therapies ... The Phase 2 PAH data readout in the middle ...

United Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales. See the ...

These findings suggest that gut microbiota composition and associated metabolites contribute to PAH development by regulating lung tissue gene expression. Our findings have implications for advancing ...

Investigators then focused on one macrophage gene involved in the ribosome signaling pathway, RPL39. Reducing the expression of RPL39 in a rat model of PAH limited macrophage proliferation in both ...

Major pharmaceutical corporations are increasingly turning to cell and gene therapies to fill possible ... a medication for pulmonary arterial hypertension (PAH), is also helping to increase ...

Meanwhile, Altavant’s lead drug is rodatristat ethyl, in mid-stage testing for pulmonary arterial hypertension (PAH), idiopathic ... has re-launched itself as a gene therapy specialist.

Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...